Mealey's (November 9, 2020, 2:28 PM EST) -- PHILADELPHIA — A biotechnology company and three of its senior executives asked a federal judge in Pennsylvania on Nov. 5 to dismiss shareholder claims that the defendants issued several misrepresentations regarding the manufacturing possibilities of the company’s COVID-19 coronavirus vaccine candidate and its selection for the federal government’s Operation Warp Speed program, arguing that shareholders failed to plead key elements of its federal securities law claims (Patrick McDermid v. Inovio Pharmaceuticals Inc., et al., No. 20-1402, E.D. Pa.)....